Jan. 7, 2013
/PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that
, the Company's Chief Executive Officer, will be presenting at the 31
Annual J.P. Morgan Healthcare Conference, being held
January 7-10, 2013
San Francisco, CA.
Mr. Bentsur's presentation is scheduled to take place on
Thursday, January 10
9:00 AM Pacific Standard Time
12:00 PM EST
A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at
. An archived version of the webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The U.S.-based Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2 development for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in
for the treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx is headquartered in New York City.
Director - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail:
SOURCE Keryx Biopharmaceuticals, Inc.